Translation of basic science into clinical medicine: novel targets for diabetic nephropathy.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Nephrology, Dialysis and Transplantation

• Publication date

  2009-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/ndt/gfp028PMID 19211649
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism

  2008cited by this paper
• A Novel Sartan Derivative With Very Low Angiotensin II Type 1 Receptor Affinity Protects the Kidney in Type 2 Diabetic Rats

  2008cited by this paper
• Inhibition of Plasminogen Activator Inhibitor-1: Its Mechanism and Effectiveness on Coagulation and Fibrosis

  2008cited by this paper
• Regulation of adult erythropoiesis by prolyl hydroxylase domain proteins.

  2008cited by this paper
• A novel class of advanced glycation inhibitors ameliorates renal and cardiovascular damage in experimental rat models.

  2007cited by this paper
• Cobalt ameliorates renal injury in an obese, hypertensive type 2 diabetes rat model.

  2007cited by this paper
• A Novel Class of Prolyl Hydroxylase Inhibitors Induces Angiogenesis and Exerts Organ Protection Against Ischemia

  2007cited by this paper
• A novel inhibitor of advanced glycation and endoplasmic reticulum stress reduces infarct volume in rat focal cerebral ischemia.

  2007cited by this paper
• Thiazolidinediones provide better renoprotection than insulin in an obese, hypertensive type II diabetic rat model.

  2007cited by this paper
• Essential Role for Prolyl Hydroxylase Domain Protein 2 in Oxygen Homeostasis of the Adult Vascular System

  2007cited by this paper
• Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.

  2006cited by this paper
• Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist.

  2006cited by this paper
• Blood oxygen level dependent (BOLD) MRI: A novel technique for the detection of myocardial ischemia.

  2006cited by this paper
• Insulin Resistance, Hyperinsulinemia, and Renal Injury: Mechanisms and Implications

  2006cited by this paper
• Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure.

  2005cited by this paper
• Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy.

  2005cited by this paper
• In a type 2 diabetic nephropathy rat model, the improvement of obesity by a low calorie diet reduces oxidative/carbonyl stress and prevents diabetic nephropathy.

  2005cited by this paper
• Plasminogen activator inhibitor-1 deficiency retards diabetic nephropathy.

  2005cited by this paper
• Renoprotective properties of angiotensin receptor blockers beyond blood pressure lowering.

  2005cited by this paper
• Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial.

  2004cited by this paper
• Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1.

  2004cited by this paper
• Depletion of Intracellular Ascorbate by the Carcinogenic Metals Nickel and Cobalt Results in the Induction of Hypoxic Stress*

  2004cited by this paper
• Oxygen sensing by HIF hydroxylases

  2004influential reference
• Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model.

  2003cited by this paper
• Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study.

  2003cited by this paper
• Renal diffusion and BOLD MRI in experimental diabetic nephropathy

  2003cited by this paper
• A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis.

  2003cited by this paper
• Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms.

  2002cited by this paper
• Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy.

  2002cited by this paper
• Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy.

  1998cited by this paper
• Effect of Troglitazene on Microalbuminuria in Patients With Incipient Diabetic Nephropathy

  1998cited by this paper

• Coagulation and Hemostasis in Diabetic Nephropathy

  2018cites this paper
• Analysis of the inhibition of PAI-1 by metal theaflavin complexes and their degradation products.

  2013cites this paper
• Plasminogen activator inhibitor-1 in kidney pathology (Review).

  2013cites this paper
• Can drinking black tea fight diabetes: literature review and theoretical indication

  2012cites this paper
• The Effects of Anti-Inflammatory and Anti-Angiogenic DNA Vaccination on Diabetic Nephropathy in Rats

  2012cites this paper
• Can inactivators of plasminogen activator inhibitor alleviate the burden of obesity and diabetes? (Review).

  2011cites this paper
• Novel Drug Treatment for Diabetic Nephropathy

  2011cites this paper
• Diabetic nephropathy: a disorder of oxygen metabolism?

  2010cites this paper
• Combating Combination of Hypertension and Diabetes in Different Rat Models

  2010cites this paper
• Angiotensin II type 1A receptor deficiency and longevity.

  2009cites this paper
• The vaptans ante portas: a status report.

  2009cites this paper